​

Terns Pharmaceuticals Ownership | Who Owns Terns Pharmaceuticals?

OverviewForecastFinancialsChart

Terns Pharmaceuticals Ownership Summary

Terns Pharmaceuticals is owned by 95.42% institutional investors, 0.29% insiders, and 4.29% retail investors. Soleus capital management is the largest institutional shareholder, holding 8.87% of TERN shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.43% of its assets in Terns Pharmaceuticals shares.

TERN Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockTerns Pharmaceuticals95.42%0.29%4.29%
SectorHealthcare Stocks 42.54%10.83%46.63%
IndustryBiotech Stocks 45.22%10.75%44.04%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Soleus capital management8.13M8.87%$61.03M
Morgan stanley7.59M8.29%$56.99M
Orbimed advisors7.56M8.26%$56.80M
Deep track capital, lp7.50M8.18%$56.29M
Vivo capital6.90M7.53%$51.79M
Commodore capital lp5.70M6.22%$42.81M
Blackrock funding, inc. /de5.55M6.06%$41.69M
Blackrock4.12M5.53%$28.06M
Vanguard group4.56M4.98%$34.24M
Adage capital partners gp3.94M4.30%$29.58M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Acorn capital advisors1.97M7.52%$14.80M
Superstring capital management lp789.65K5.84%$5.93M
Vivo capital6.90M4.17%$51.79M
Acuta capital partners502.80K3.90%$3.78M
Soleus capital management8.13M3.07%$61.03M
Commodore capital lp5.70M2.09%$42.81M
Deep track capital, lp7.50M1.57%$56.29M
Timessquare capital management621.64K1.45%$92.18M
Orbimed advisors7.56M1.34%$56.80M
Robeco schweiz411.27K1.17%$60.99M

Top Buyers

HolderShares% AssetsChange
Commodore capital lp5.70M2.09%5.70M
Adage capital partners gp3.94M0.05%2.66M
Norges bank849.39K0.00%849.39K
Blackrock4.12M0.00%804.98K
Nuveen asset management2.63M0.00%617.01K

Top Sellers

HolderShares% AssetsChange
Avidity partners management lp---2.13M
Janus henderson group---2.00M
Octagon capital advisors lp---1.36M
Suvretta capital management---1.36M
Schonfeld strategic advisors1.89M0.08%-1.16M

New Positions

HolderShares% AssetsChangeValue
Commodore capital lp5.70M2.09%5.70M$42.81M
Norges bank849.39K0.00%849.39K$4.71M
Platinum investment management125.16K0.06%125.16K$939.92K
Stempoint capital lp89.62K0.13%89.62K$673.02K
Prudential financial69.12K0.00%69.12K$519.09K

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-9.00
True wealth design-11.00
Capital performance advisors llp-23.00
Farther finance advisors-27.00
Versant capital management-36.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 20251396.92%87,383,3715.14%951.16%67-6.94%4033.33%
Jun 30, 2025129-7.19%83,090,778-0.02%901.10%711.43%30-23.08%
Mar 31, 2025139-13.66%83,111,324-3.50%900.74%70-33.33%3921.88%
Dec 31, 2024149-9.70%81,944,1563.09%1051.01%94-8.74%31-18.42%
Sep 30, 202416517.86%79,491,27019.38%1021.28%1038.42%3865.22%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv2.12M2.43%-47.20K
Vanguard US Total Market Shares ETF2.09M2.39%792.70K
iShares Russell 2000 ETF1.77M2.02%-
Belfius Equities Cure C Cap1.29M1.47%-
Fidelity Select Biotechnology1.09M1.29%1.09M
Candriam Eqs L Biotech C USD Cap1.08M1.24%-
CREF Stock R11.08M1.23%-160.00K
T. Rowe Price New Horizons1.04M1.23%-
US Small-Cap Growth II Equity Comp1.04M1.23%529.45K
Fidelity Small Cap Growth877.41K1.04%-1.09M

Recent Insider Transactions

DateNameRoleActivityValue
Nov 04, 2025Quigley Jill M.-Sell$441.36K
Oct 01, 2025Kuriakose Emil Chief Medical OfficerSell$7.41K
Jul 01, 2025Kuriakose Emil Chief Medical OfficerSell$3.64K
Jun 27, 2025Gengos Andrew Chief Financial OfficerBuy$19.65K
Jun 27, 2025Gengos Andrew Chief Financial OfficerBuy$19.63K

Insider Transactions Trends

DateBuySell
2025 Q4-2
2025 Q3-1
2025 Q261
2025 Q1-5
2024 Q41-

TERN Ownership FAQ

Who Owns Terns Pharmaceuticals?

Terns Pharmaceuticals shareholders are primarily institutional investors at 95.42%, followed by 0.29% insiders and 4.29% retail investors. The average institutional ownership in Terns Pharmaceuticals's industry, Biotech Stocks , is 45.22%, which Terns Pharmaceuticals exceeds.

Who owns the most shares of Terns Pharmaceuticals?

Terns Pharmaceuticals’s largest shareholders are Soleus capital management (8.13M shares, 8.87%), Morgan stanley (7.59M shares, 8.29%), and Orbimed advisors (7.56M shares, 8.26%). Together, they hold 25.42% of Terns Pharmaceuticals’s total shares outstanding.

Does Blackrock own Terns Pharmaceuticals?

Yes, BlackRock owns 5.53% of Terns Pharmaceuticals, totaling 4.12M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 28.06M$. In the last quarter, BlackRock increased its holdings by 804.98K shares, a 24.28% change.

Who is Terns Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Acorn capital advisors is Terns Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 7.52% of its assets in 1.97M Terns Pharmaceuticals shares, valued at 14.8M$.

Who is the top mutual fund holder of Terns Pharmaceuticals shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Terns Pharmaceuticals shares, with 2.43% of its total shares outstanding invested in 2.12M Terns Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools